Lexicon Pharmaceuticals, Inc.LXRX

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · lexpharma.com

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives, with a pipeline of drug candidates in discovery, preclinical and clinical development for neuropathic pain, hypertrophic cardiomyopathy, obesity/metabolic disorders and other cardiometabolic indications. Its approved product sotagliflozin (an SGLT1/SGLT2 inhibitor) has been studied in heart failure, diabetes and chronic kidney disease.

Key ratios

FCF / Sales

-136.2%2025

2024 -578.5%2023 -13485.3%

Net margin

-147.4%TTM

2025 -101.1%

ROA

-14.3%TTM

2025 -12.7%2024 -46.4%2023 -50.7%

ROE

-40.2%TTM

2025 -39.7%2024 -167.7%2023 -168.5%

Revenue growth

-29.0%TTM

2025 60.2%2024 2481.5%2023 766.2%

Recent news

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure 2026-08-31 · GlobeNewswire

Track LXRX in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer